Back to homepage

Psychiatry

Suvorexant for insomnia in older adults: a perspective review

Authors: Rajesh R Tampi, Geetha Manikkara, Silpa Balachandran, Piyush Taparia, Stephanie Hrisko, Shilpa Srinivasan, Deena J Tampi

This review identifies published randomized control trials that evaluate the efficacy and tolerability of suvorexant for the treatment of insomnia among older adults.

More

Practical outpatient pharmacotherapy for alcohol use disorder

Authors: Youngjung Kim, Laura Hack, Elizabeth S Ahn, Jungjin Kim

This article discusses practical pharmacotherapy strategies to improve treatment outcome for alcohol use disorder.

More

Analgesics in the management of behavioral and psychological symptoms of dementia: a perspective review

Authors: Rajesh R Tampi, Corey Hassell, Pallavi Joshi, Deena J Tampi

This review assesses the efficacy and tolerability of analgesics in reducing behavioral and psychological symptoms of dementia among older adults from published randomized controlled trials.

More

Corrigendum: Pharmacoeconomic comparison of aripiprazole once-monthly and paliperidone palmitate from a head-to-head clinical trial in schizophrenia: a US analysis

Authors: Christophe Sapin, Ann Hartry, Siddhesh A Kamat, Maud Beillat, Ross A Baker, Anna Eramo

The authors wish to make the following corrections to their article: Sapin C, Hartry A, Kamat SA, Beillat M, Baker RA, Eramo A. Pharmacoeconomic comparison of aripiprazole once-monthly and paliperidone palmitate from a head-to-head clinical trial in schizophrenia: a US analysis. Drugs in Context 2016; 5: 212301. DOI: 10.7573/dic.212301

More

Pharmacoeconomic comparison of aripiprazole once-monthly and paliperidone palmitate from a head-to-head clinical trial in schizophrenia: a US analysis

Authors: Christophe Sapin, Ann Hartry, Siddhesh A Kamat, Maud Beillat, Ross A Baker, Anna Eramo

In this analysis the authors used health economics assessment data collected during the QUAlity of LIfe with AbiliFY Maintena (QUALIFY) study, a randomized head-to-head study of aripiprazole once-monthly 400 mg (AOM 400) compared with paliperidone palmitate (PP; 78–234 mg/mo), to determine the direct medical and pharmacy costs and the cost-effectiveness associated with each treatment over 6 months. The authors concluded that the analysis of data from stabilized patients with schizophrenia in the QUALIFY study indicated that AOM 400 is associated with lower health-care costs and greater effectiveness compared with PP and thus represents the economically dominant strategy.

More